BPC-157 TB-500 is a two-peptide research blend with no controlled combination trial.

What the Wolverine peptide blend is

BPC-157 TB-500 — marketed as the "Wolverine" peptide blend — is not one molecule. It is a research-community pairing of two distinct synthetic peptides discussed together as a tissue-repair stack. BPC-157 is a 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV, ~1419.5 Da) derived from a partial sequence of a protein found in human gastric juice ^[1]. TB-500 is a synthetic N-acetylated heptapeptide, Ac-LKKTETQ (~889 Da), corresponding to residues 17-23 — the actin-binding motif — of the 43-residue intracellular protein Thymosin Beta-4 ^[5][6].

The blend has no single molecular weight, no CAS number, and no standardized composition. Commercial "Wolverine" vials are commonly labeled with a combined per-vial mass — a 10 mg + 10 mg BPC-157:TB-500 pairing, for instance — but no ratio is clinically validated, and no peer-reviewed combination dose-finding study exists ^[9]. As a wolverine peptide term, the name is also conflated with the X-Men character in search data; here it refers strictly to this two-peptide construct.

This site occupies the "doctor" position the domain name implies in one narrow sense only: it reads the regulatory and access record as carefully as it reads the science. It is an editorial console, not a clinic. The clearest single fact about the pairing is the absence at its center — two mechanisms theorized to converge, and not one trial that tested the convergence.

BPC 157 TB 500: blend identity at a glance

BPC 157 TB 500 reduces to two readouts. BPC-157 is the cytoprotective, pro-angiogenic channel: it up-regulates VEGFR2 with downstream Akt-eNOS signaling and modulates the nitric-oxide system ^[2]. TB-500 is the cytoskeletal channel: its LKKTETQ helix binds monomeric G-actin 1:1, regulating the actin dynamics that drive cell migration ^[3].

The two channels are largely non-overlapping. BPC-157 acts at the cell surface and in the extracellular repair environment; TB-500 acts intracellularly on the actin pool. That separation is the whole basis of the "synergy" idea — complementary, not redundant, mechanisms. It is also why the idea stays theoretical: complementarity on a mechanism diagram is not a measured combined effect ^[4].

BPC-157 and TB-500: the two peptides a clinician would distinguish

BPC-157 and TB-500 differ in structure, size, and mechanism, and a careful reader keeps them apart. BPC-157 is a 15-mer derived from a gastric-juice protein; its characterized role is a local angiogenic and cytoprotective signal acting through VEGFR2 up-regulation and internalization with downstream Akt-eNOS activation ^[2]. In a transected rat Achilles tendon model it accelerated healing across biomechanical, functional, microscopic, and macroscopic measures ^[1].

TB-500 is a 7-mer fragment of Thymosin Beta-4. Crystallography of a thymosin-beta-4–actin complex resolved at 2 Å established that the parent peptide forms a 1:1 complex with G-actin and sequesters the monomer by capping both ends, preventing polymerization — the structural basis for the fragment's actin-binding mechanism ^[3]. One identity caveat runs through everything written about TB-500: the overwhelming majority of efficacy data attributed to it were generated with full-length Thymosin Beta-4 (~4963 Da), not the marketed 7-mer ^[4]. Read more on how BPC-157 and TB-500 differ in mechanism.

The per-constituent literature is mature on mechanism and entirely preclinical on efficacy. The cross-cutting question — what the two do together in a person — has no answer in the published record.

BPC-157 TB-500 stack: why it is a research-community label, not a clinical regimen

The BPC-157 TB-500 "stack" is a community label, not an approved product or a validated regimen. A 2025 systematic review of BPC-157 in orthopaedic sports medicine screened 36 studies — 35 preclinical, one human — and makes no mention of TB-500 or any combination use ^[7]. There is no peer-reviewed study that defines a synergy ratio, dose, or endpoint for the two given together ^[4].

The practical consequence sits on every section of this site: each finding belongs to one constituent, read against that constituent's own studies. The blend-level claim — that the pairing heals injuries faster than either peptide alone — has no human data behind it. That is the honest frame for the combination rationale and the unproven synergy claim, and the reason the converging "repair signal" stays unlit on the readout above.

Where the access and regulatory record stands

Neither constituent is an FDA-approved drug, and the blend has no approved therapeutic indication anywhere. Both BPC-157 and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" currently sit in FDA's 503A Category 2 — bulk drug substances FDA has identified as potentially presenting significant safety risks — effective with the September 29, 2023 update to FDA's nominated-substances list ^[10]. Both are also prohibited in sport by the World Anti-Doping Agency.

There is forward motion worth noting honestly: an FDA Pharmacy Compounding Advisory Committee meeting is scheduled for July 23-24, 2026 to discuss BPC-157 and TB-500 as candidates for the Section 503A bulks list — a scheduled evaluation, not a decision ^[12]. The full record, including how lawful compounded access works, sits on the Wolverine legal status and FDA 503A compounding access page. Quantitative findings are detailed on BPC-157 TB-500 tendon and ligament repair research, and dose context on BPC-157 TB-500 dosage in the research literature.